Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark: On a fast growth track - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 21, 2001

    Glenmark: On a fast growth track

    Glenmark Pharmaceuticals Ltd, one of the leading pharma companies in dermatology segment (which deals with skin infections) has shown an impressive performance for the year ended March'01. While, sales have improved by 32%, operating margins have shown a improvement of more than 500 basis points which is remarkable. However, higher interest and depreciation expenses marred bottomline growth which showed a negative performance of 21%.

    (Rs m) FY00 FY01 % Change
    Sales 1,453 1,923 32.3%
    Other Income 155 21 -86.3%
    Expenditure 1,300 1,624 24.9%
    Operating Profit (EBDIT) 153 299 95.4%
    Operating Profit Margin (%) 10.5% 15.5% 47.7%
    Interest 10 83 700.3%
    Depreciation 11 51 359.5%
    Profit before Tax 287 186 -35.1%
    Extraordinary Income - - -
    Tax 70 15 -78.1%
    Profit after Tax/(Loss) 217 171 -21.2%
    Net profit margin (%) 14.9% 8.9%  
    No. of Shares (eoy) (m) 10.0 10.1  
    Diluted Earnings per share* 21.7 16.9  
    P/E (at current price) 5.6 7.2  
    (*- annualised)      

    Glenmark is a leader in the dermatology segment which contributes around 40% to its turnover. Last year it acquired Flucort (Lyka brand) to cater to the steroid market in the dermatology segment. The company has also identified the anti-diabetes market as a key growth area in future. A separate marketing force catering specifically to the anti-diabetic market has also been set up, comprising an all-India sales force of 130 medical representatives. In addition, it is also planning to launch insulins shortly. The competition is limited with only four companies catering to the insulin segment.

    Glenmark is striving to take a lead in research activities. In a significant development the company has recently filed patent for a new anti-asthma drug, that is currently completing pre-clinical trials. The company has also initiated dialogues with various MNCs for collaborative research projects.

    At the current market price of Rs 122, the stock is quoting at 7 times its FY01 earnings. Given the initiatives taken by the company and focus on niche therapeutic segments one can expect the pace of growth to continue in future.



    Equitymaster requests your view! Post a comment on "Glenmark: On a fast growth track". Click here!


    More Views on News

    Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

    May 18, 2017

    Base price erosion in the US and lower Zetia sales impacts profits.

    Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

    Feb 15, 2017

    Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

    Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

    Nov 8, 2016

    Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 10:50 AM


    • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Detailed Quarterly Results With Charts